Ahead of July 22 Vote, Avanos Reveals Stockholder Lawsuits and Supplements Merger Proxy
AVNS has more than doubled off its 52-week low of $9.303 on light trading volume (0.2× avg).
Summary
Avanos Medical faces two stockholder lawsuits seeking to block its $25.00 per share merger with American Industrial Partners, and has supplemented its proxy with J.P. Morgan's valuation analyses showing implied equity values below the deal price. The special meeting remains scheduled for July 22, 2026.
Key Events · M&A and Partnerships · AVNS
-
Stockholder Lawsuits Filed
On June 29-30, 2026, two purported stockholders filed actions in New York Supreme Court (Williams and Stevens) seeking to enjoin the merger and alleging disclosure deficiencies in the definitive proxy statement.
-
Supplemental Proxy Disclosures
Voluntarily, Avanos supplemented the proxy with additional details on UBS conflicts (estimated fee up to $5 million), AIP's non-discussion of executive employment terms, and J.P. Morgan's valuation analyses.
-
J.P. Morgan Valuation Ranges Below Deal Price
The public trading multiples analysis implied a per share equity value of $12.75–$23.50, while the selected transactions analysis implied $9.75–$21.75—both below the $25.00 merger consideration.
-
Special Meeting on July 22, 2026
The special meeting to vote on the merger remains scheduled for July 22, 2026; the board unanimously recommends voting FOR all proposals.
Analysis · AVNS · Industrial Applications And Services
Just weeks before its July 22 special meeting, Avanos Medical disclosed two stockholder lawsuits aiming to block the $25.00 per share acquisition by American Industrial Partners. The company also supplemented its proxy with detailed financial analyses from J.P. Morgan, which show implied per share equity value ranges of $12.75–$23.50 from public trading multiples and $9.75–$21.75 from selected transactions—both below the $25.00 merger consideration. Although the board continues to recommend the deal, the litigation and the valuation gap highlighted in the new disclosures could sway shareholder voting and introduce uncertainty into the closing timeline.
At the time of this filing, AVNS was trading at $24.93 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.30 to $25.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.